EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study

Chia-Chih Kuo, Min-Hsiang Chuang, Chun-Hsien Li, Po-Yu Huang, Hsing-Tao Kuo, Chih-Cheng Lai

Hepatology International · 2025

DOI: 10.1007/s12072-024-10752-9 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hepatology International, 2025. Verfasst von Chia-Chih Kuo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseGlucagon-Like PeptidesHypoglycemic AgentsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedDipeptidyl-Peptidase IV InhibitorsAdultSodium-Glucose Transporter 2 InhibitorsThiazolidinedionesLiver TransplantationCarcinoma, HepatocellularLiver NeoplasmsGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

Diabetes mellitusMajor adverse liver outcomesNonalcoholic fatty liver diseaseSemaglutide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsThiazolidinedionesGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
  • Department of Physical Medicine and Rehabilitation, Chi Mei Medical Center, Tainan, Taiwan.
  • Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan. kht@mail.chimei.org.tw.
  • School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan. kht@mail.chimei.org.tw.
  • Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan. dtmed141@gmail.com.
  • School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan. dtmed141@gmail.com.

Zitieren

APA

Kuo, C. C., Chuang, M. H., Li, C. H., Huang, P. Y., Kuo, H. T., & Lai, C. C. (2025). Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study. Hepatology International. https://doi.org/10.1007/s12072-024-10752-9

Vancouver

Kuo CC, Chuang MH, Li CH, Huang PY, Kuo HT, Lai CC. Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study. Hepatology International. 2025. doi:10.1007/s12072-024-10752-9

BibTeX
@article{Kuo2025,
  author = {Kuo, Chia-Chih and Chuang, Min-Hsiang and Li, Chun-Hsien and Huang, Po-Yu and Kuo, Hsing-Tao and Lai, Chih-Cheng},
  title = {Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study},
  journal = {Hepatology International},
  year = {2025},
  doi = {10.1007/s12072-024-10752-9}
}
Kostenlos starten →